Dublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "Invasive Ductal Carcinoma Treatment Market by Therapy, by Type, by Distribution Channel, and By Region" report has been added to ResearchAndMarkets.com's offering.
The steadily climbing incidence of breast cancer worldwide has catalyzed significant growth in the global invasive ductal carcinoma treatment market, with projections estimating an increase from USD 9.37 billion in 2023 to USD 23.02 billion by 2034. The market is anticipated to experience a compound annual growth rate (CAGR) of 8.52% over the forecast period of 2024-2034. Factors propelling this expansion include advancements in personalized medicine, a surge in research and development, and improved healthcare accessibility in emerging economies.
Targeted Therapy Leading the Therapeutic Approach
In the realm of therapeutic strategies, targeted therapy clinched the top revenue-generating segment in 2023. Personalized medicine's rising adoption, coupled with the targeted approach's efficacy and reduced side effects, underscores this trend. Future market predictions highlight the immunotherapy segment's rapid growth trajectory owing to its innovative applications in treatment-resistant cases and burgeoning position in combination therapy regimens.
Focused Treatment for Hormone Receptor-positive Cancers
By type, hormone receptor-positive invasive ductal carcinoma forms a substantial revenue portion, with existing therapies like tamoxifen and aromatase inhibitors proving effective for these cancer types. The HER2+ segment is also expected to witness accelerated growth as new, more potent HER2-targeting treatments come to the fore.
Hospital Pharmacies Dominate Distribution Channels
Hospital pharmacies emerged as the leading distribution channel within the market—owing largely to the high volume of cancer therapies dispensed in hospital settings and the exclusivity of advanced treatments. However, growth in online pharmacies is projected as technology continues to streamline health commerce, facilitating easier medication access for patients.
Regional Market Dynamics
North America holds the majority of the revenue share, a direct result of its robust healthcare framework and the prevalence of breast cancer in the region. Meanwhile, the Asia Pacific zone is slated to exhibit the most rapid CAGR, propelled by the burgeoning healthcare infrastructure and amplified awareness and access to treatment options.
The industry's growth trajectory underscores a dynamic market environment, ripe with invention and driven by an urgent healthcare priority—managing one of the most prevalent cancer forms effectively. For further information on this market development, interested parties are encouraged to engage with relevant stakeholders and follow updates issued by authoritative healthcare bodies and cancer research organizations.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value (USD) in 2023 | $9.37 Billion |
| Forecasted Market Value (USD) by 2034 | $23.02 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
Companies Featured
- Roche Holding AG
- Novartis AG
- Pfizer Inc.
- Merck & Co. Inc.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Eli Lilly and Company
- Sanofi S.A.
- Gilead Sciences Inc.
- Amgen Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Seattle Genetics Inc.
- AbbVie Inc.
- Johnson & Johnson.
For more information about this report visit https://www.researchandmarkets.com/r/cwh5qi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
